10-HYDROXYWARFARIN
10-HYDROXYWARFARIN structure
|
Common Name | 10-HYDROXYWARFARIN | ||
|---|---|---|---|---|
| CAS Number | 83219-99-2 | Molecular Weight | 324.32700 | |
| Density | 1.388 g/cm3 | Boiling Point | 509.2ºC at 760 mmHg | |
| Molecular Formula | C19H16O5 | Melting Point | 183-185ºC | |
| MSDS | Chinese USA | Flash Point | 185ºC | |
| Symbol |
GHS05, GHS06 |
Signal Word | Danger | |
| Name | 4-hydroxy-3-(2-hydroxy-3-oxo-1-phenylbutyl)chromen-2-one |
|---|---|
| Synonym | More Synonyms |
| Density | 1.388 g/cm3 |
|---|---|
| Boiling Point | 509.2ºC at 760 mmHg |
| Melting Point | 183-185ºC |
| Molecular Formula | C19H16O5 |
| Molecular Weight | 324.32700 |
| Flash Point | 185ºC |
| Exact Mass | 324.10000 |
| PSA | 87.74000 |
| LogP | 2.58040 |
| Index of Refraction | 1.656 |
| Symbol |
GHS05, GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H300-H318 |
| Precautionary Statements | P264-P280-P301 + P310-P305 + P351 + P338 |
| Personal Protective Equipment | Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges |
| Hazard Codes | T: Toxic; |
| Risk Phrases | 25-41 |
| Safety Phrases | 26-39-45 |
| RIDADR | UN 2811 6 |
|
Investigation of two-dimensional high performance liquid chromatography approaches for reversed phase resolution of warfarin and hydroxywarfarin isomers.
J. Chromatogr. A. 1363 , 200-6, (2014) Several offline and online 2D HPLC methods were investigated for the reversed phase resolution of a complex mixture of closely related warfarin and hydroxywarfarin isomers. By combining reversed phase... |
|
|
Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.
Chem. Res. Toxicol. 23(5) , 939-45, (2010) Coumadin (R/S-warfarin) anticoagulant therapy poses a risk to over 50 million Americans, in part due to interpersonal variation in drug metabolism. Consequently, it is important to understand how meta... |
|
|
Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin.
Drug Metab. Lett. 4(4) , 213-9, (2010) Effective coumadin (R/S-warfarin) therapy is complicated by inter-individual variability in metabolism. Recent studies have demonstrated that CYP3A isoforms likely contribute to patient responses and ... |
| 10-Hydroxywarfarin |